

BAXTER INTERNATIONAL INC.
Net Sales
Periods Ending December 31, 2011 and 2010
(unaudited)
(\$ in millions)

	Q4 2011	Q4 2010	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2011	YTD 2010	% Growth @ Actual Rates	% Growth @ Constant Rates
BioScience								
United States	\$735	\$703	5%	5%	\$2,805	\$2,615	7%	7%
International	840	830	1%	1%	3,248	3,025	7%	3%
Total BioScience	\$1,575	\$1,533	3%	3%	\$6,053	\$5,640	7%	5%
Medical Products¹								
United States ^{2,3}	\$726	\$731	(1%)	(1%)	\$2,870	\$2,828	1%	1%
International	1,287	1,225	5%	4%	4,934	4,542	9%	4%
Total Medical Products - Adjusted^{2,3}	\$2,013	\$1,956	3%	2%	\$7,804	\$7,370	6%	3%
COLLEAGUE infusion pump charge ²	-	-			-	(213)		
Total Medical Products - GAAP^{2,3}	\$2,013	\$1,956	3%	2%	\$7,804	\$7,157	9%	6%
Transfusion Therapies⁴								
United States	\$5	\$6	(17%)	(17%)	\$34	\$34	1%	1%
International	1	3	(67%)	(67%)	2	12	(86%)	(82%)
Total Transfusion Therapies	\$6	\$9	(33%)	(33%)	\$36	\$46	(22%)	(21%)
Baxter International Inc.								
United States ^{2,3}	\$1,466	\$1,440	2%	2%	\$5,709	\$5,477	4%	4%
International	2,128	2,058	3%	3%	8,184	7,579	8%	4%
Total Baxter - Adjusted^{2,3}	\$3,594	\$3,498	3%	3%	\$13,893	\$13,056	6%	4%
COLLEAGUE infusion pump charge ²	-	-			-	(213)		
Total Baxter - GAAP^{2,3}	\$3,594	\$3,498	3%	3%	\$13,893	\$12,843	8%	6%

¹ Medical Products represents the combination of the company's former Medication Delivery and Renal businesses into a single global business unit. Effective January 1, 2011, the company changed its segment presentation to reflect this new structure, and recast all prior periods presented to conform to the new presentation.

² GAAP net sales in the first quarter of 2010 included a charge of \$213 million related to the recall of COLLEAGUE infusion pumps. Refer to page 18 for a reconciliation to GAAP measures.

³ Included net sales related to the U.S. multi-source generic injectables business through the May 2011 divestiture date. The impact on adjusted net sales for total Medical Products and total Baxter was as follows (\$ in millions):

	Q4 2011	Q4 2010	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2011	YTD 2010	% Growth @ Actual Rates	% Growth @ Constant Rates
Total Medical Products - Adjusted²	\$2,013	\$1,956	3%	2%	\$7,804	\$7,370	6%	3%
U.S. multi-source generic injectables business	-	(55)			(58)	(198)		
Total Medical Products - Adjusted (Excluding U.S. Multi-Source Generic Injectables Business)	\$2,013	\$1,901	6%	5%	\$7,746	\$7,172	8%	5%
Total Baxter - Adjusted²	\$3,594	\$3,498	3%	3%	\$13,893	\$13,056	6%	4%
U.S. multi-source generic injectables business	-	(55)			(58)	(198)		
Total Baxter - Adjusted (Excluding U.S. Multi-Source Generic Injectables Business)	\$3,594	\$3,443	4%	4%	\$13,835	\$12,858	8%	5%

⁴ Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the Transfusion Therapies (TT) business after the February 2007 divestiture.